Silexion Therapeutics Reports Positive Preclinical Findings for SIL204

What Happened

• On August 4, 2026, Silexion Therapeutics Corp. filed a Form 8-K (Item 7.01, Regulation FD disclosure) to furnish a press release titled “Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers.” The press release is included as Exhibit 99.1 to the Form 8-K. The disclosure reports new positive preclinical data for Silexion’s development candidate SIL204 showing multi-mechanism immune sensitization activity in KRAS-driven cancers.

Key Details

• Filing date: August 4, 2026 (Form 8-K, Item 7.01, Regulation FD disclosure).
• Press release title: “Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers.”
• Topic: Positive preclinical findings for SIL204 (multi-mechanism immune sensitization) in KRAS-driven cancers.
• Press release furnished as Exhibit 99.1 to the Form 8-K.

Why It Matters

• The company disclosed positive preclinical data for SIL204, signaling progress in its oncology pipeline and providing investors with an update on scientific development milestones.
• This is a Regulation FD filing to ensure the market is informed; the Form 8-K does not include financial results or clinical trial outcomes beyond the preclinical findings described in the press release.